Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

advanced breast cancer

EU flag

Second Remicade biosimilar given green light in Europe

Samsung Bioepis’ Flixabi provides another lower-cost treatment option

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

- PMLiVE

J&J gets European OK for myeloma therapy Darzalex

First-in-class immunotherapy achieved ‘significant increase’ in overall survival

China drug medicine pharma prices

Prices of AZ and GSK drugs slashed in China

GSK says price reductions represent  “defining moment” in improving patient outcomes

AstraZeneca AZ global R&D corporate HQ

AZ gets orphan status for selumetinib in thyroid cancer

Drug already in phase III testing for KRAS-mutant advanced NSCLC

- PMLiVE

Cell Therapy licenses heart failure therapy in Japan

EMA may grant Welsh-based biotech a marketing application in mid-2016

UK flag

UK biopharma says Brexit would be “bad for business”

Over 90 industry leaders sign letter supporting the Remain campaign

eHealth set to benefit from EC’s ‘single digital market’

Says will help European industry, researchers and public authorities

Deal Watch March 2016

AstraZeneca, Roche, Sanofi and Valeant are featured in this month’s roundup of pharma deals

AstraZeneca AZ

CHMP backs AZ’s ‘superbug’ antibiotic product

Zavicefta recommended for European approval

AstraZeneca AZ

AZ adds gout drug Zurampic to asset sale

Ironwood Pharmaceuticals buys exclusive US rights to the therapy and follow-up product

Eli Lilly HQ

Lilly’s psoriasis drug Taltz cleared in Europe

Clinicians suggest the IL-17 inhibitor has “best-in-class data”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links